Crossref

1. Symptom report and treatment experience of hypogonadal men with and without type 2 diabetes in a United States health plan

- E. F. Shortridge

- P. Polzer

- P. Donga

- R. L. Wade

2. Clinical and epidemiological characteristics of male hypogonadism in type 2 diabetes in Russia: combined analysis of study data for the period 2005–2022

- M. O. Chernova

- D. I. Esaulenko

- E. R. Rozhivanova

- R. V. Rozhivanov

- G. A. Mel’nichenko

- M. V. Shestakova

- N. G. Mokrysheva

3. Metabolic syndrome as cardiovascular risk factor in childhood cancer survivors

- V.G. Pluimakers

- M. van Waas

- S.J.C.M.M. Neggers

- M.M. van den Heuvel-Eibrink

4. The incidence and aggravating factors of male hypogonadism in type 2 diabetes

- R. V. Rozhivanov

- M. O. Chernova

- G. A. Mel’nichenko

- M. V. Shestakova

- N. G. Mokrysheva

5. Metabolic syndrome components and prostatic hyperplasia among diabetic and non-diabetic men in the Eastern DR Congo: A cross-sectional study

- L.E. Mubenga

- D. Gruson

- M.P. Hermans

- E. Bwenge

- B. Tombal

6. Serum testosterone in Nigerian men with type 2 diabetes mellitus and its relationship with insulin sensitivity and glycemic control

- Ngamariju Sepu

- Jokotade O. Adeleye

- Modupe O. Kuti